{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:34:33Z","timestamp":1787063673447,"version":"build-2736575974"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2016,5,15]],"date-time":"2016-05-15T00:00:00Z","timestamp":1463270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aims of this study were to describe the prevalence of QRS prolongation and abnormal QRS morphology in patients with heart failure and preserved ejection fraction (HF-PEF) and to examine the relationship between these QRS abnormalities and clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We categorized patients in the Irbesartan in Heart Failure with Preserved Ejection Fraction trial (I-PRESERVE) according to QRS duration &amp;lt;120 vs. \u2265120 ms and QRS morphology: normal, left bundle branch block (LBBB), and right bundle branch block (RBBB) or other non-specific intra-ventricular conduction defect (IVCD). The outcomes examined were the composite of cardiovascular death or heart failure hospitalization (and its components) and all-cause mortality. Of the 4128 patients enrolled in I-PRESERVE, 3754 were included in the present analyses. A total of 606 patients had a QRS duration \u2265120 ms, 302 had LBBB and 742 had RBBB\/IVCD. Patients with an abnormal QRS had evidence of more severe heart failure [lower left ventricular ejection fraction, lower estimated glomerular filtration rate, higher N-terminal pro-B-type natriuretic peptide (NT-proBNP)] and worse clinical status (higher New York Heart Association functional class and greater use of diuretics). Both abnormalities of QRS duration and QRS morphology were associated with worse outcomes. The rates of the composite outcome were: 6.0 and 9.3 per 100 patient years in the &amp;lt;120 ms and \u2265120 ms groups, respectively [adjusted hazard ratio (HR) 1.32, 95% confidence interval (CI) 1.11\u20131.57; P = 0.002) and 6.0, 7.7 and 8.7 per 100 patient years in the normal, non-LBBB and LBBB groups, respectively (adjusted HR 1.19, 95% CI 1.00\u20131.42, P = 0.046; and HR 1.31, 95% CI 1.03\u20131.66, P = 0.026, respectively, compared with normal). The heightened risk related to QRS abnormalities persisted after adjustment for other prognostic variables, including NT-proBNP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We found that both prolongation of QRS duration and abnormal QRS morphology were associated with a high risk of fatal and non-fatal adverse outcomes in heart failure with preserved ejection fraction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.547","type":"journal-article","created":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T21:53:20Z","timestamp":1463608400000},"page":"1021-1031","source":"Crossref","is-referenced-by-count":20,"title":["Clinical Outcomes According to Qrs Duration and Morphology in the Irbesartan in Patients with Heart Failure and Preserved Systolic Function (I-PRESERVE) Trial"],"prefix":"10.1093","volume":"18","author":[{"given":"Jane A.","family":"Cannon","sequence":"first","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, BHF Cardiovascular Research Centre, University of Glasgow , Glasgow, G12 8TA, Scotland ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Shen","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, BHF Cardiovascular Research Centre, University of Glasgow , Glasgow, G12 8TA, Scotland ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, BHF Cardiovascular Research Centre, University of Glasgow , Glasgow, G12 8TA, Scotland ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inder S.","family":"Anand","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Minnesota , Minneapolis, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Komajda","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris 6 and Hospital Piti\u00e9-Salp\u00e9tri\u00e8re , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"McKelvie","sequence":"additional","affiliation":[{"name":"Hamilton Health Sciences, McMaster University , Hamilton, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Zile","sequence":"additional","affiliation":[{"name":"Ralph H. Johnsons Veterans Affairs Medical Center and, Medical University of South Carolina , Charleston, SC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Carson","sequence":"additional","affiliation":[{"name":"Georgetown University and Washington DC Veterans Affairs Medical Center , Washington, DC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, BHF Cardiovascular Research Centre, University of Glasgow , Glasgow, G12 8TA, Scotland ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,5,15]]},"reference":[{"key":"2026011721154795900_ejhf547-bib-0001","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0167-5273(95)02502-2","article-title":"Natural history of abnormal conduction and its relation to prognosis in patients with dilated cardiomyopathy","volume":"53","author":"Xiao","year":"1996","journal-title":"Int J Cardiol"},{"key":"2026011721154795900_ejhf547-bib-0002","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1161\/01.CIR.95.12.2660","article-title":"Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation","volume":"95","author":"Aaronson","year":"1997","journal-title":"Circulation"},{"key":"2026011721154795900_ejhf547-bib-0003","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0002-9149(88)90225-1","article-title":"Serial electrocardiographic changes in idiopathic dilated cardiomyopathy confirmed at necropsy","volume":"62","author":"Wilensky","year":"1998","journal-title":"Am J Cardiol"},{"key":"2026011721154795900_ejhf547-bib-0004","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0167-5273(99)00077-7","article-title":"Intraventricular conduction delay: a prognostic marker in chronic heart failure","volume":"70","author":"Shamim","year":"1999","journal-title":"Int J Cardiol"},{"key":"2026011721154795900_ejhf547-bib-0005","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"2026011721154795900_ejhf547-bib-0006","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"2026011721154795900_ejhf547-bib-0007","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.acvd.2010.01.009","article-title":"Is cardiac resynchronization therapy an option in heart failure patients with preserved ejection fraction? Justification for the ongoing KaRen project","volume":"103","author":"Donal","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"key":"2026011721154795900_ejhf547-bib-0008","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/eurheartj\/ehs305","article-title":"Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction","volume":"34","author":"Lund","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011721154795900_ejhf547-bib-0009","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/eurheartj\/eht427","article-title":"Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction","volume":"35","author":"Santos","year":"2014","journal-title":"Eur Heart J"},{"key":"2026011721154795900_ejhf547-bib-0010","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"2026011721154795900_ejhf547-bib-0011","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejheart.2007.12.010","article-title":"Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial","volume":"10","author":"McMurray","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026011721154795900_ejhf547-bib-0012","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCHEARTFAILURE.109.932996","article-title":"Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE)","volume":"4","author":"Komajda","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2026011721154795900_ejhf547-bib-0013","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1067\/mhj.2002.121264","article-title":"Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure","volume":"143","author":"Baldasseroni","year":"2002","journal-title":"Am Heart J"},{"key":"2026011721154795900_ejhf547-bib-0014","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.cardfail.2008.07.238","article-title":"Prognostic importance of change in QRS duration over time associated with left ventricular dysfunction in patients with congestive heart failure: the DIAMOND study","volume":"14","author":"Fosbol","year":"2008","journal-title":"J Card Fail"},{"key":"2026011721154795900_ejhf547-bib-0015","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ejheart.2006.11.006","article-title":"Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme","volume":"9","author":"Hawkins","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2026011721154795900_ejhf547-bib-0016","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1001\/jama.299.22.2656","article-title":"Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction","volume":"299","author":"Wang","year":"2008","journal-title":"JAMA"},{"key":"2026011721154795900_ejhf547-bib-0017","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1161\/CIRCHEARTFAILURE.113.000326","article-title":"Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure","volume":"6","author":"Linde","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026011721154795900_ejhf547-bib-0018","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/01.CIR.0000095027.28753.9D","article-title":"Prognostic significance of corrected QT and corrected JT interval for incident coronary heart disease in a general population sample stratified by presence or absence of wide QRS complex: the ARIC Study with 13 years of follow-up","volume":"108","author":"Crow","year":"2003","journal-title":"Circulation"},{"key":"2026011721154795900_ejhf547-bib-0019","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/01.HYP.0000217141.20163.23","article-title":"Electrocardiographic QRS duration and the risk of congestive heart failure: the Framingham Heart Study","volume":"47","author":"Dhingra","year":"2006","journal-title":"Hypertension"},{"key":"2026011721154795900_ejhf547-bib-0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCHEARTFAILURE.109.932996","article-title":"Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE)","volume":"4","author":"Komajda","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2026011721154795900_ejhf547-bib-0021","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1161\/CIRCULATIONAHA.114.009625","article-title":"Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction","volume":"131","author":"Mohammed","year":"2015","journal-title":"Circulation"},{"key":"2026011721154795900_ejhf547-bib-0022","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1093\/eurheartj\/eht290","article-title":"An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure","volume":"34","author":"Cleland","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011721154795900_ejhf547-bib-0023","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ahj.2014.08.004","article-title":"Is mechanical dyssynchrony a therapeutic target in heart failure with preserved ejection fraction?","volume":"168","author":"Menet","year":"2014","journal-title":"Am Heart J"},{"key":"2026011721154795900_ejhf547-bib-0024","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1306687","article-title":"Cardiac-resynchronization therapy in heart failure with a narrow QRS complex","volume":"369","author":"Ruschitzka","year":"2013","journal-title":"N Engl J Med"},{"key":"2026011721154795900_ejhf547-bib-0025","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000368795","article-title":"Acute effects of biventricular pacing in heart failure patients with a normal ejection fraction and mechanical dyssynchrony","volume":"130","author":"Wang","year":"2015","journal-title":"Cardiology"},{"key":"2026011721154795900_ejhf547-bib-0026","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ejhf.327","article-title":"Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response","volume":"17","author":"Kao","year":"2015","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.547","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.547","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/18\/8\/1021\/66382826\/eurjhf_18_8_1021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/18\/8\/1021\/66382826\/eurjhf_18_8_1021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:16:26Z","timestamp":1768702586000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/18\/8\/1021\/8423232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,15]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,5,15]]},"published-print":{"date-parts":[[2016,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.547","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,8]]},"published":{"date-parts":[[2016,5,15]]}}}